Amneal Pharmaceuticals Inc (AMRX)

Mar 3, 2025, 4:05 PM EST - 5 days ago

Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Feb 28, 2025, 2:20 PM EST - 8 days ago

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 6:00 AM EST - 8 days ago

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 1:42 PM EST - 12 days ago

Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock

Feb 19, 2025, 8:00 AM EST - 17 days ago

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

Jan 29, 2025, 8:30 AM EST - 5 weeks ago

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Jan 23, 2025, 8:00 AM EST - 6 weeks ago

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Dec 4, 2024, 8:00 AM EST - 3 months ago

Amneal to Participate at Upcoming Investor Conferences

Nov 21, 2024, 4:05 PM EST - 3 months ago

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Nov 8, 2024, 3:27 PM EST - 4 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 6:00 AM EST - 4 months ago

Amneal Reports Third Quarter 2024 Financial Results

Oct 21, 2024, 8:00 AM EDT - 4 months ago

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

Oct 8, 2024, 4:05 PM EDT - 5 months ago

Amneal to Report Third Quarter 2024 Results on November 8, 2024

Oct 1, 2024, 6:00 AM EDT - 5 months ago

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

Sep 23, 2024, 8:00 AM EDT - 5 months ago

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease

Sep 5, 2024, 4:05 PM EDT - 6 months ago

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Aug 20, 2024, 9:45 AM EDT - 7 months ago

Melina Kennedy Joins the LDI, Ltd. Board of Managers

WBTN

Aug 20, 2024, 8:00 AM EDT - 7 months ago

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Aug 9, 2024, 12:14 PM EDT - 7 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 6:05 AM EDT - 7 months ago

Amneal Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:45 PM EDT - 7 months ago

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson's Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Jul 29, 2024, 4:05 PM EDT - 7 months ago

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Jul 11, 2024, 4:05 PM EDT - 8 months ago

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Jul 10, 2024, 11:40 AM EDT - 8 months ago

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 9, 2024, 4:05 PM EDT - 8 months ago

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

Jul 1, 2024, 8:00 AM EDT - 8 months ago

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Jul 1, 2024, 8:00 AM EDT - 8 months ago

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

Jun 28, 2024, 8:00 AM EDT - 9 months ago

Amneal Releases 2023 Environmental, Social and Governance Report

Jun 5, 2024, 8:00 AM EDT - 9 months ago

Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies

May 22, 2024, 4:05 PM EDT - 10 months ago

Amneal to Participate at Upcoming Investor Conference

May 22, 2024, 4:05 PM EDT - 10 months ago

Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California

May 3, 2024, 1:37 PM EDT - 11 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript

May 3, 2024, 11:00 AM EDT - 11 months ago

Drugmaker Amneal agrees to $270 million U.S. opioid settlement

May 3, 2024, 6:00 AM EDT - 11 months ago

Amneal Reports First Quarter 2024 Financial Results

Apr 29, 2024, 10:48 PM EDT - 11 months ago

California teams with Amneal Pharma for cheaper, generic version of Narcan

Apr 24, 2024, 8:00 AM EDT - 11 months ago

Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Apr 16, 2024, 8:00 AM EDT - 11 months ago

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Apr 10, 2024, 8:00 AM EDT - 11 months ago

Amneal to Report First Quarter 2024 Results on May 3, 2024

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

Mar 25, 2024, 4:05 PM EDT - 1 year ago

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

Mar 1, 2024, 12:26 PM EST - 1 year ago

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript

Mar 1, 2024, 6:00 AM EST - 1 year ago

Amneal Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 8:00 AM EST - 1 year ago

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

Feb 8, 2024, 4:05 PM EST - 1 year ago

Amneal Announces Complete Response Resubmission for IPX203 New Drug Application

Jan 31, 2024, 4:05 PM EST - 1 year ago

Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024

Jan 25, 2024, 7:30 AM EST - 1 year ago

Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203

Jan 10, 2024, 8:00 AM EST - 1 year ago

Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension

Jan 4, 2024, 4:05 PM EST - 1 year ago

Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023

Dec 22, 2023, 12:15 PM EST - 1 year ago

GSK, Amneal, Kaléo delist patents from FDA's orange book

GSK